NO20054072L - Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist. - Google Patents

Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.

Info

Publication number
NO20054072L
NO20054072L NO20054072A NO20054072A NO20054072L NO 20054072 L NO20054072 L NO 20054072L NO 20054072 A NO20054072 A NO 20054072A NO 20054072 A NO20054072 A NO 20054072A NO 20054072 L NO20054072 L NO 20054072L
Authority
NO
Norway
Prior art keywords
antagonist
therapeutic agent
spinal cord
cord injury
interleukin
Prior art date
Application number
NO20054072A
Other languages
English (en)
Other versions
NO20054072D0 (no
Inventor
Hideyuki Okano
Seiji Okada
Masaya Nakamura
Kazuyuki Yoshizaki
Original Assignee
Univ Keio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio filed Critical Univ Keio
Publication of NO20054072D0 publication Critical patent/NO20054072D0/no
Publication of NO20054072L publication Critical patent/NO20054072L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

2005-10-25 Sammendrag Et terapeutisk middel for ryggmargsskade, en modulator for differensiering av nevrale stamceller og en hemmer av differensiering til gliaceller omfattende en interieukin-6 antagonist som en aktiv bestanddel.
NO20054072A 2003-02-24 2005-09-01 Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist. NO20054072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003046214 2003-02-24
PCT/JP2004/002111 WO2004073741A1 (ja) 2003-02-24 2004-02-24 インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤

Publications (2)

Publication Number Publication Date
NO20054072D0 NO20054072D0 (no) 2005-09-01
NO20054072L true NO20054072L (no) 2005-10-25

Family

ID=32905544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054072A NO20054072L (no) 2003-02-24 2005-09-01 Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.

Country Status (16)

Country Link
US (1) US20060165696A1 (no)
EP (1) EP1607100A4 (no)
JP (1) JP4555924B2 (no)
KR (1) KR101142624B1 (no)
CN (2) CN100340294C (no)
AU (1) AU2004212843B2 (no)
BR (1) BRPI0407747A (no)
CA (1) CA2516945A1 (no)
HR (1) HRP20050837A2 (no)
IL (3) IL170399A (no)
MX (1) MXPA05008713A (no)
NO (1) NO20054072L (no)
NZ (1) NZ541928A (no)
PL (1) PL378199A1 (no)
RU (2) RU2358761C2 (no)
WO (1) WO2004073741A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) * 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7709215B2 (en) * 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP6097702B2 (ja) 2011-03-03 2017-03-15 アペクシジェン， インコーポレイテッド 抗ｉｌ−６受容体抗体およびその使用方法
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
KR20220064039A (ko) 2020-11-11 2022-05-18 정성삼 척수 손상 예방 또는 치료용 조성물
KR102320780B1 (ko) 2021-01-29 2021-11-02 정성삼 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521628A (en) 1894-06-19 Housekeeping-cabinet
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
DK0811384T3 (da) * 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
EP1027059A2 (en) * 1997-10-27 2000-08-16 Curis, Inc. Enhancement of morphogen activity
JP2002503460A (ja) * 1998-02-13 2002-02-05 ザ ウィスター インスティテュート 創傷治癒のための組成物および方法
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders

Also Published As

Publication number Publication date
HK1088230A1 (zh) 2006-11-03
JPWO2004073741A1 (ja) 2007-08-23
US20060165696A1 (en) 2006-07-27
EP1607100A4 (en) 2007-06-13
RU2005130011A (ru) 2006-02-10
RU2358761C2 (ru) 2009-06-20
NO20054072D0 (no) 2005-09-01
WO2004073741A8 (ja) 2005-04-07
PL378199A1 (pl) 2006-03-06
HRP20050837A2 (en) 2005-12-31
KR101142624B1 (ko) 2012-06-15
RU2009102845A (ru) 2010-08-10
EP1607100A1 (en) 2005-12-21
CN101130077A (zh) 2008-02-27
CA2516945A1 (en) 2004-09-02
IL200098A (en) 2012-10-31
IL205618A (en) 2012-02-29
NZ541928A (en) 2009-06-26
WO2004073741A1 (ja) 2004-09-02
CN100340294C (zh) 2007-10-03
BRPI0407747A (pt) 2006-02-14
CN1753694A (zh) 2006-03-29
AU2004212843A1 (en) 2004-09-02
IL170399A (en) 2011-02-28
JP4555924B2 (ja) 2010-10-06
AU2004212843B2 (en) 2009-06-25
KR20060006004A (ko) 2006-01-18
MXPA05008713A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
BRPI0407747A (pt) agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
DK1478399T3 (da) Oral dosisform indeholdende en pde-4-inhibitor som en aktiv bestanddel og polyvinylpyrrolidone som excipiens
DK1364946T3 (da) Isoxazolin-derivat og herbicid omfattende samme som aktiv bestanddel
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
NO20064127L (no) Terapeutisk middel for Auris interna forstyrrelse, inneholdende IL-6 antagonist som aktiv bestanddel
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
NO20074697L (no) Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20054681L (no) Farmasoytiske produkter
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
GB0222514D0 (en) Organic compounds
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
DE602005024704D1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
NO20062150L (no) Nye ketooksadiazolderivater som katepsinhibitorer
NO20070431L (no) Kjemiske forbindelser I
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application